These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7739851)

  • 41. Relative versus absolute carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with acute alcoholic hepatitis.
    Halm U; Tannapfel A; Mössner J; Berr F
    Alcohol Clin Exp Res; 1999 Oct; 23(10):1614-8. PubMed ID: 10549992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study.
    Bolukbas FF; Bolukbas C; Horoz M; Gumus M; Erdogan M; Zeyrek F; Yayla A; Ovunc O
    BMC Gastroenterol; 2004 Sep; 4():23. PubMed ID: 15387890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serum triglycerides in chronic hepatopathies].
    Coniglio S; Marchetti L; Torchio G; Colombo E; Gaido A; Giorgi S
    G Clin Med; 1979 Jul; 60(7):515-8. PubMed ID: 548290
    [No Abstract]   [Full Text] [Related]  

  • 44. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
    Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Significance of the study of bile salts in acute and chronic liver disease].
    D'Aquino M; Della Sala S; Fazzin G; Michieletto L; Saonato F
    Quad Sclavo Diagn; 1987 Jun; 23(2):132-6. PubMed ID: 3451290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance.
    Fujimoto M; Uemura M; Nakatani Y; Tsujita S; Hoppo K; Tamagawa T; Kitano H; Kikukawa M; Ann T; Ishii Y; Kojima H; Sakurai S; Tanaka R; Namisaki T; Noguchi R; Higashino T; Kikuchi E; Nishimura K; Takaya A; Fukui H
    Alcohol Clin Exp Res; 2000 Apr; 24(4 Suppl):48S-54S. PubMed ID: 10803780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis.
    Zietz B; Lock G; Plach B; Drobnik W; Grossmann J; Schölmerich J; Straub RH
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):495-501. PubMed ID: 12702906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.
    Trak-Smayra V; Dargere D; Noun R; Albuquerque M; Yaghi C; Gannagé-Yared MH; Bedossa P; Paradis V
    Gut; 2009 Jun; 58(6):825-32. PubMed ID: 18403495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin response and clearance in acute and chronic liver disease.
    Sette H; Hughes RD; Langley PG; Gimson AE; Williams R
    Thromb Haemost; 1985 Oct; 54(3):591-4. PubMed ID: 4089794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease].
    Zimmerer J; Tittor W; Degen P
    Fortschr Med; 1982 Sep; 100(36):1683-8. PubMed ID: 7141370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyrosine metabolism in patients with liver disease.
    Levine RJ; Conn HO
    J Clin Invest; 1967 Dec; 46(12):2012-20. PubMed ID: 6074004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zinc status in chronic liver disease; studies in Nigerian patients.
    Gusau KA; Elegbede JA; Idoko JA; Wali SS
    West Afr J Med; 1990; 9(4):245-51. PubMed ID: 2083200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elimination of paracetamol in chronic liver disease.
    Arnman R; Olsson R
    Acta Hepatogastroenterol (Stuttg); 1978 Aug; 25(4):283-6. PubMed ID: 696204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sulfadimidine kinetics in patients with various chronic liver diseases.
    Horváth T; Past T; Par A; Kádas I; Jávor T
    Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver function and medroxyprogesterone acetate elimination in man.
    Rautio A
    Biomed Pharmacother; 1984; 38(4):199-204. PubMed ID: 6498308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases].
    Del Prete S; Malacco E; Bonzi G; Natelli A; Roncoroni S; Jalanbo H
    Minerva Med; 1975 Mar; 66(22):1051-7. PubMed ID: 1124151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impaired elimination of caffeine in cirrhosis.
    Desmond PV; Patwardhan RV; Johnson RF; Schenker S
    Dig Dis Sci; 1980 Mar; 25(3):193-7. PubMed ID: 7371463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
    Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Caffeine test assessment for measuring liver function in critically ill patients.
    Calatayud O; Rodríguez M; Sánchez-Alcaraz A; Ibáñez P
    J Clin Pharm Ther; 1995 Feb; 20(1):23-9. PubMed ID: 7775610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of the value of serum caffeine and bile acid concentrations as indicators of liver injury].
    Habior A; Ostrowski J; Trzeciak L; Wojciechowski K
    Pol Arch Med Wewn; 1990 Nov; 84(5):284-91. PubMed ID: 2075120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.